REVB — Revelation Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Revelation Biosciences Announces Future Clinical Development Plans Based On Recent Biomarker Analysis And Significant Reduction In New Collagen Deposition (Fibrosis) In Preclinical Model
Brief: Revelation Biosciences Inc Announces Financial Results For The Three And Nine Months Ended Sept 30, 2022
U.S. STOCKS ON THE MOVE-Centene, Rite Aid Corp, MSCI
Revelation Biosciences jump on positive data for new kidney diseases drug
Brief: Revelation Biosciences Inc. Announces Positive Results In Preclinical Model Of Acute And Chronic Kidney Disease
U.S. STOCKS ON THE MOVE-Alphabet, Sylvamo, Compass
U.S. STOCKS ON THE MOVE-Pinterest, Take-Two, energy sector
Revelation Biosciences up on license deal for infection drug
Brief: Revelation Biosciences And Vanderbilt University Enter Exclusive Worldwide License Agreement
Brief: Revelation Biosciences Announces Results For Quarter Ended June 30
Brief: Revelation Biosciences Inc Announces Pricing Of $5 Million Public Offering
U.S. STOCKS ON THE MOVE-ToughBuilt Industries Inc, Koss Corp, Centene Corp
U.S. STOCKS ON THE MOVE-Lakeland Financial, World Wrestling Entertainment, Bank of Marin
U.S. STOCKS ON THE MOVE-Soligenix, Veru, American Express
U.S. STOCKS ON THE MOVE-Tesla Inc, MP Materials Corp, Revelation Bioscience
Revelation Biosciences shares more than double on allergy treatment data
Brief: Revelation Biosciences Announces Topline Data For Phase 1B Clear Clinical Study Of Revtx-99B For Treatment Of Allergic Rhinitis
Brief: Revelation Biosciences Inc Completes Database Lock For Its Phase 1B Clear Clinical Study For The Treatment Of Allergic Rhinitis
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM